Talking brain health at Aberdeen Wellbeing Festival

Visit the Scottish Brain Sciences team at the Aberdeen Health and Wellbeing Festival on 10 January 2026. Reserve free tickets today.

Championing women’s brain health

A new review from the Women’s Brain Foundation, with involvement from the team at Scottish Brain Sciences, suggests that women’s higher risk of dementia may be linked to estrogen.

Celebrating our new clinical research site in Aberdeen

We celebrated the opening of our new Aberdeen research centre at ONE BioHub on 14 November with an event for our local participants, stakeholders and customers.

Accelerating Alzheimer’s Research webinar: Insights for professionals supporting people living with Alzheimer’s

We are sharing the latest updates on clinical trials, new treatment pathways, and the role of cognitive sciences in early detection and prevention.

AFC Women Show Their Support for Brain Health

The Aberdeen FC Women’s team have helped us share an important message about the power of research and the need for better treatments for Alzheimer’s.

Golf and Brain Health: A New Partnership with Big Potential

Scottish Brain Sciences partners with Golf in Society to promote healthy ageing and brain health through the power of golf.

Scottish Brain Sciences joins forces with Aberdeen FC Women

Scottish Brain Sciences is now an Official Partner of Aberdeen FC Women for the 2025/26 season.

Scottish Rugby legend Dr James Robson tackles brain health in new role

Scottish Brain Sciences (SBS) is proud to announce the appointment of Dr James Robson, MBE, one of the UK’s most respected sports medicine experts, as Sport and Wellbeing Medical Advisor.  

Our Edinburgh research centre is moving!

We are delighted to share that we are moving our Edinburgh base and headquarters to a newly refurbished research facility within Scottish Gas Murrayfield stadium.

Lecanemab is approved by MHRA in Great Britain, and restricted in NHS

Following today’s announcements from the MHRA and NICE about a new drug, lecanemab – which approve its use in Great Britain, but block its adoption in NHS England – our CEO and Founder, Prof Craig Ritchie has responded.